Latest filing published 07 Jan 2025 for Intellia Therapeutics, Inc., €77k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Derek Hicks: trading record in brief
Derek Hicks, listed as chief executive, appears in our data through filings on Intellia Therapeutics, Inc. shares, published by SEC (Form 4). The record holds 6 filings, for trades running from 3 January 2022 to 3 January 2025.
Every open-market trade on record is a sale: 3 sales worth €245k. Other entries cover 3 share grants. 2025 to date brings no purchases and 1 sale.
The newest entry dates from 7 January 2025: an open-market sale of €77k, in Intellia Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Derek Hicks
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,502 shares@ US$12.1831.4% of flowCommon StockSEC:0000950170-25-003014:0
- 29,393 shares0Common StockSEC:0000950170-24-025903:0
- 3,877 shares@ US$29.4642.5% of flowCommon StockSEC:0000950170-24-002507:0
- 23,558 shares0Common StockSEC:0001209191-23-015817:0
- 1,812 shares@ US$37.2126.0% of flowCommon StockSEC:0001209191-23-002421:0
- 19,118 shares0Common StockSEC:0001209191-22-001651:0
6 of 6 declarations
